Related Experiment Video
Updated: Jan 21, 2026

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion
Published on: December 13, 2024
The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver
Tina Hörbelt1, Birgit Knebel2, Pia Fahlbusch1
1Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center at the Heinrich-Heine-University Duesseldorf, Leibniz Center for Diabetes Research, Auf'm Hennekamp 65, 40225 Duesseldorf, Germany; German Center of Diabetes Research Partner, Duesseldorf, Germany; Medical Faculty, Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Heinrich Heine University, Düsseldorf, Germany.
Abstract:
Secreted frizzled-related protein (sFRP) 4 is an adipokine with increased expression in white adipose tissue from obese subjects with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Yet, it is unknown whether sFRP4 action contributes to the development of these pathologies. Here, we determined whether sFRP4 expression in visceral fat associates with NAFLD and whether it directly interferes with insulin action and lipid and glucose metabolism in primary hepatocytes and myotubes. The association of sFRP4 with clinical measures was investigated in obese men with or without type 2 diabetes and with or without biopsy-proven NAFLD. To determine the impact of sFRP4 on metabolic parameters, primary human myotubes (hSkMC), or primary hepatocytes from metabolic healthy C57Bl6 and from systemic insulin-resistant mice, i.e. aP2-SREBP-1c, were used. Gene expression of sFRP4 in visceral fat from obese men associated with insulin sensitivity, triglycerides and NAFLD. In C57Bl6 hepatocytes, sFRP4 disturbed insulin action. Specifically, sFRP4 decreased the abundance of IRS1 and FoxO1 together with impaired insulin-mediated activation of Akt-signalling and glycogen synthesis and a reduced suppression of gluconeogenesis by insulin. Moreover, sFRP4 enhanced insulin-stimulated hepatic de novo lipogenesis (DNL). In hSkMC, sFRP4 induced glycolysis rather than inhibiting insulin signalling. Finally, in hepatocytes from aP2-SREBP-1c mice, sFRP4 potentiates existing insulin resistance. Collectively, we show that sFRP4 interferes with hepatocyte insulin action. Physiologically, sFRP4 promotes DNL in hepatocytes and glycolysis in myotubes. These sFRP4-mediated responses may result in a vicious cycle, in which enhanced rates of DNL and glycolysis aggravate hepatic lipid accumulation and insulin resistance.
Insights
Secreted frizzled-related protein 4 (sFRP4) in visceral fat is linked to non-alcoholic fatty liver disease (NAFLD) and insulin resistance. sFRP4 disrupts insulin action in liver cells, promoting fat synthesis and worsening metabolic dysfunction.
Area of Science:
- Metabolic disease research
- Endocrinology
- Molecular biology
Background:
- Secreted frizzled-related protein 4 (sFRP4) is an adipokine with elevated expression in obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).
- The precise role of sFRP4 in the development of these metabolic pathologies remains unclear.
Purpose of the Study:
- To investigate the association between visceral fat sFRP4 expression and NAFLD in obese men.
- To determine if sFRP4 directly impacts insulin action, lipid, and glucose metabolism in primary human hepatocytes and myotubes.
Main Methods:
- Association study of sFRP4 gene expression in visceral fat with clinical parameters (insulin sensitivity, triglycerides, NAFLD) in obese men.
- In vitro studies using primary human skeletal muscle cells (hSkMC) and primary hepatocytes from metabolic healthy and insulin-resistant mice (aP2-SREBP-1c).
- Analysis of insulin signaling pathways, glycogen synthesis, gluconeogenesis, and de novo lipogenesis (DNL) in response to sFRP4 treatment.
Main Results:
- Visceral fat sFRP4 expression correlated with insulin sensitivity, triglyceride levels, and the presence of NAFLD in obese men.
- In hepatocytes, sFRP4 impaired insulin signaling by reducing IRS1 and FoxO1, inhibiting insulin-mediated Akt activation and glycogen synthesis, and reducing gluconeogenesis suppression.
- sFRP4 promoted insulin-stimulated hepatic de novo lipogenesis (DNL) and induced glycolysis in myotubes, exacerbating insulin resistance in hepatocytes from insulin-resistant mice.
Conclusions:
- sFRP4 in visceral fat is associated with NAFLD and insulin resistance.
- sFRP4 directly interferes with hepatocyte insulin action, promoting hepatic DNL and glycolysis in myotubes.
- These actions of sFRP4 may contribute to a cycle of hepatic lipid accumulation and worsening insulin resistance.
Related Concept Videos
Insulin Secretory Vesicles
Resistivity
Resistance
Insulin: The Receptor and Signaling Pathways
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

